Abstract
Acquired eosinophilia is currently classified into secondary (reactional to underlying diseases), clonal (presence of a bone marrow histological, cytogenetic or molecular marker of a myeloid malignancy) and idiopathic (neither secondary nor clonal) categories. We report the case of a 47-year-old male who was admitted to the hospital for Staphylococcus aureus recurring infections. An hypereosinophilia was discovered and led to molecular analysis. The identification of FIP1L1-PDGFRA fusion gene permitted the diagnostic of clonal eosinophilia. Treatment by imatinib mesylate induced an haematological remission, the control of the infection and thoracotomy cicatrization. This case is original because of its infectious presentation and the efficacy of imatinib mesylate to control the infectious process.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Anti-Bacterial Agents / therapeutic use
-
Benzamides
-
Biomarkers / metabolism
-
Clone Cells / pathology
-
Eosinophilia / diagnosis*
-
Eosinophilia / drug therapy
-
Eosinophilia / genetics
-
Eosinophilia / microbiology*
-
Gene Rearrangement
-
Humans
-
Imatinib Mesylate
-
Male
-
Middle Aged
-
Piperazines / therapeutic use*
-
Protein Kinase Inhibitors / therapeutic use*
-
Pyrimidines / therapeutic use*
-
Receptor, Platelet-Derived Growth Factor alpha / genetics
-
Recurrence
-
Risk Factors
-
Smoking / adverse effects
-
Staphylococcal Infections / complications*
-
Staphylococcus aureus* / drug effects
-
Staphylococcus aureus* / isolation & purification
-
Treatment Outcome
-
mRNA Cleavage and Polyadenylation Factors / genetics
Substances
-
Anti-Bacterial Agents
-
Benzamides
-
Biomarkers
-
FIP1L1 protein, human
-
Piperazines
-
Protein Kinase Inhibitors
-
Pyrimidines
-
mRNA Cleavage and Polyadenylation Factors
-
Imatinib Mesylate
-
Receptor, Platelet-Derived Growth Factor alpha